Functional genetic studies have demonstrated that SHP2 is required for survival in RTK-driven cancer models, including those driven by oncogenic epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and fibroblast growth factor receptor (FGFR) alterations20. The gene discussed is ALK; the disease is cancer.